Cancer News and Research

Latest Cancer News and Research

ifp Institut für Produktqualität sells molecular biological, PCR-based food test product line to QIAGEN

The Berlin-based diagnostics company ifp Institut für Produktqualität has sold its molecular biological, PCR-based food test product line to QIAGEN at a price not revealed. QIAGEN has purchased all the required patents and licences and will immediately begin to market and distribute the newly acquired portfolio of 70 molecular biological tests. With the support of this powerful and experienced partner in food diagnostics ifp can now make available its expertise in food analytics globally.

From QIAGEN Manchester Limited 26 May 2010

Breast-conserving therapy is viable treatment option for African-American women: Researchers

Breast-conserving therapy is a viable treatment option for African-American women, although they tend to have more advanced breast cancer at diagnosis, according to researchers from Beaumont Hospitals, Royal Oak, Mich. The study is available online now and will be in the July 15 issue of the journal Cancer.

26 May 2010

Highlights from June 2010 issue of American Journal of Pathology

Dr. Kanneboyina Nagaraju and colleagues at the Children's National Medical Center, Washington, DC demonstrate that affected muscle may directly contribute to inflammation in muscular dystrophy. Their report can be found in the June 2010 issue of The American Journal of Pathology.

26 May 2010

Silence Therapeutics deepens diverse portfolio of RNAi intellectual property

Silence Therapeutics plc announces the issuance of United States patent 7,723,316, titled Compositions and Methods of RNAi Therapeutics For Treatment of Cancer and Other Neovascularization Disease, by the United States Patent and Trademark Office (USPTO).

26 May 2010

Consequences of secrecy in medicine

No one knows how many mothers' and babies' lives have been saved by the obstetrical forceps. This device has been part of the standard equipment of every maternity room for about 250 years. However, a shadow lies over the success story: after the Chamberlen brothers developed the device at the beginning of the 17th century, the brothers and their descendants used it for 3 generations, but kept it a secret from other obstetricians.

26 May 2010

Liberty National Life Insurance to open new distribution offices in Voluntary Benefits Worksite and Senior Markets

Liberty National Life Insurance Company, a subsidiary of Torchmark Corporation, today announced a major strategic initiative to open 50 new company-sponsored distribution offices nationwide in the Voluntary Benefits Worksite and Senior Markets.

26 May 2010

Researchers describe carcinogenic effects of EDCs

Longtime environmental health researchers at Tufts University School of Medicine describe the carcinogenic effects of endocrine-disrupting chemicals, ubiquitous chemicals that have hormone-like effects in the body. In a review article published online May 25 in Nature Reviews Endocrinology, the researchers express the need for more complex strategies for studying how these chemicals affect health but report that ample evidence already supports changing public health and environmental policies to protect the public from exposure to EDCs.

26 May 2010

EIRMC, West Valley Medical Center to continue to serve Humana's Medicare Advantage members

Eastern Idaho Regional Medical Center (EIRMC), a full-service regional medical center in Idaho Falls, and West Valley Medical Center, a community hospital in Caldwell, will continue to provide in-network medical care to all Medicare Advantage members enrolled in plans offered by Humana, under terms of a renewal agreement announced today.

26 May 2010

Workplace wellness programs improve employer's bottom line

"Who has time?" is a frequent question in response to the suggestion of a medical check-up. Job demands aren't becoming easier to meet in this challenging economy. And there is always a "to-do" list waiting at home. Naturally employees feel these pressures.

26 May 2010

Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept

EpiCept Corporation today announced that the targeted enrollment in a Phase IIb trial for EpiCept NP-1 in chemotherapy-induced peripheral neuropathy has been attained. The trial is being conducted by National Cancer Institute -funded Community Clinical Oncology Program.

26 May 2010

NIDDK awards Albert Einstein College of Medicine $9.5M for continuation of Diabetes Research and Training Center

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has awarded Albert Einstein College of Medicine of Yeshiva University a five-year, $9.5 million grant for the continuation of its Diabetes Research and Training Center (DRTC). The DRTC was also awarded a $632,000 supplemental grant for equipment and additional pilot and feasibility studies through the American Recovery and Reinvestment Act (ARRA), bringing total NIH support to $10,177,000.

26 May 2010

Defect in cellular pathways provides new explanation for earliest stages of craniosynostosis in newborns

University of Rochester Medical Center scientists discovered a defect in cellular pathways that provides a new explanation for the earliest stages of abnormal skull development in newborns, known as craniosynostosis.

26 May 2010

RCSI researchers identify biomarker that can predict severity of breast cancer

Researchers from the Royal College of Surgeons in Ireland have identified a biomarker in patient blood which can predict the severity of breast cancer in patients and may enable clinicians to track patients throughout the course of their treatment.

26 May 2010

NASH-induced cirrhosis is greater risk factor for HCC: Cleveland Clinic study

A study conducted by researchers at the Cleveland Clinic finds that patients suffering from cirrhosis preceded by nonalcoholic steatohepatitis are at an equal risk of developing hepatocellular carcinoma than those who develop cirrhosis resulting from hepatitis C virus. Results of this study appear in the June issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

26 May 2010

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.

26 May 2010

Immunomedics announces receipt of $5M from Nycomed for reaching clinical milestone

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced the receipt of $5 million from Nycomed for reaching a clinical milestone under the license and collaboration agreement, entered into on July 11, 2008.

26 May 2010

QIAGEN acquires rights to 70 molecular food safety tests developed by Institute for Product Quality

QIAGEN today announced that it has entered into an agreement with the Institute for Product Quality (ifp), pursuant to which QIAGEN has acquired all rights to 70 molecular food safety tests developed by the Berlin-based specialized laboratory center for food analysis.

From QIAGEN Manchester Limited 26 May 2010

State Roundup: Oklahoma, S.C. and Ill. facing tough choices on health costs

States around the country are debating how to deal with health costs and tight budgets.

26 May 2010

GTx reports top line results from toremifene Phase III clinical trial for prostate cancer

GTx, Inc. today announced top line results of the Phase III clinical trial evaluating toremifene 20 mg, a selective estrogen receptor modulator, for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia, or PIN, a premalignant lesion of the prostate.

26 May 2010

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.

25 May 2010

Cancer News and Research

Latest Cancer News and Research

ifp Institut für Produktqualität sells molecular biological, PCR-based food test product line to QIAGEN

Breast-conserving therapy is viable treatment option for African-American women: Researchers

Highlights from June 2010 issue of American Journal of Pathology

Silence Therapeutics deepens diverse portfolio of RNAi intellectual property

Consequences of secrecy in medicine

Liberty National Life Insurance to open new distribution offices in Voluntary Benefits Worksite and Senior Markets

Researchers describe carcinogenic effects of EDCs

EIRMC, West Valley Medical Center to continue to serve Humana's Medicare Advantage members

Workplace wellness programs improve employer's bottom line

Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept

NIDDK awards Albert Einstein College of Medicine $9.5M for continuation of Diabetes Research and Training Center

Defect in cellular pathways provides new explanation for earliest stages of craniosynostosis in newborns

RCSI researchers identify biomarker that can predict severity of breast cancer

NASH-induced cirrhosis is greater risk factor for HCC: Cleveland Clinic study

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Immunomedics announces receipt of $5M from Nycomed for reaching clinical milestone

QIAGEN acquires rights to 70 molecular food safety tests developed by Institute for Product Quality

State Roundup: Oklahoma, S.C. and Ill. facing tough choices on health costs

GTx reports top line results from toremifene Phase III clinical trial for prostate cancer

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

Cancer Research - Second Edition eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Newsletters you may be interested in